Mavenir and HCL Collaborate on Integration and Delivery of O-RAN Compliant Radios
14.10.2021 16:00:00 EEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced a strategic partnership with HCL Technologies (HCL), a leading global technology company with expertise in network systems testing. This partnership helps accelerate the market availability of O-RAN split 7.2 compliant Remote Radiohead Units (RRUs) while establishing a business model to meet the growing demand and evolving requirements for O-RAN RRUs.
Today’s RRU ecosystem has expanded to offer Communication Service Providers (CSPs) a significantly wider choice of 2G, 3G, 4G, 5G, massive MIMO (mMIMO), millimeter Wave (mmWave), small cell and indoor radios. In turn, the number of RRU partners that Mavenir works with continues to grow, with each partner releasing new and sophisticated radios, with new software, across different radio technologies, output power, antenna dimensions and spectrum to meet the evolving needs of O-RAN customers.
The collaboration brings together HCL’s platform for third-party RRU testing and Mavenir’s full Centralized Unit (CU) and Distributed Unit (DU) RAN software stacks. RRU vendors will, as a result, be given the ability to work directly with HCL to assess their O-RAN interfaces and integrate with Mavenir’s O-RAN compliant cloud-native CU/DU software.
By simplifying testing and validation across multiple O-RAN interoperability profiles, the collaboration will help vendors fast-track validation of frequency variants and the increasingly diverse RRU offerings being demanded by the O-RAN market.
This partnership will benefit both RRU vendors and CSPs by supporting the continued expansion of the radio ecosystem and helping to establish a self-sustaining RRU business model:
- Vendors will be able to rapidly validate their O-RAN compliant RRUs as they develop portfolios of products targeted at different deployment scenarios.
- CSPs will be able to more easily identify the available O-RAN compliant RRU options for specific use cases and locations.
“We are directly addressing requests from customers and partners to speed the integration of new RRU products. The growing scale of the O-RAN industry now demands such a model. And thanks to O-RAN and open interfaces, new players such as HCL can enter the market to effectively serve the market needs,” said Mavenir’s Puneet Sethi, SVP/GM RAN Business Unit. “As more O-RAN RRU products become available and RRU partners are enabled to respond rapidly to their customers, CSPs worldwide will be able to take advantage of the full range of their spectrum assets and benefit from the rapidly accelerating RRU ecosystem.”
“The Mavenir-HCL partnership helps accelerate the O-RAN market, bringing a new suite of product offerings to CSPs and enterprises alike. This sets the stage for a nascent ecosystem accelerating future innovation across key verticals on a global scale,” said HCL’s Rajiv Shesh, Corporate Vice President, Engineering and R&D Services. “HCL is bringing together many decades of network testing experience, 5G expertise, state of the art lab facilities and advanced automation tools to validate the interoperability between Mavenir and RRU partners. HCL provides the necessary visibility and reporting capability that enables operators and enterprises in deploying best-of-breed Mavenir O-RAN solutions.”
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005064/en/
Contact information
Maryvonne Tubb
Mavenir
PR@mavenir.com
Casey Bush
GlobalResultsPR (US)
mavenir@globalresultspr.com
Kevin Taylor
GlobalResultsPR (EMEA)
mavenir@globalresultspr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom